Roxane's Oramorph SR morphine sulfate
Boehringer Ingelheim subsidiary and Adria Labs begin comarketing 12-hour slow-release morphine for cancer pain in the U.S. The Schedule II Roxane product was approved in 30 mg, 60 mg, and 100 mg doses on Aug. 15. Roxane has marketed the 30 mg dosage since 1984 as a DESI drug under the name Roxanol SR. In 1985, FDA's pilot drug staff required both Roxane and Purdue Frederick to submit NDAs for their products due to their novel sustained release delivery systems. According to Roxane, Adria will provide about 120 of the more than 150 sales reps detailing the product.. ..
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth